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Abstract 
Background 
Payments to medical oncologists and clinical haematologists can negatively affect prescribing practice, 
but the extent of payments to these specialists is unknown in Australia. 
Aims 
We aimed to analyse the extent of payments from the pharmaceutical industry to Australian cancer 
physicians as reported during the first collated period of the Disclosure Australia website. 
Methods 
We performed a retrospective, cross-sectional analysis of payments made from November 2018 to 
April 2019, using a file downloaded from the Disclosure Australia website. We checked the names of 
listed medical practitioners against Medical Board of Australia records to assign specialties. The 
number of medical oncologists, clinical haematologists, other specialist physicians and non-specialist 
physician medical practitioners was calculated, along with the payments to each of these groups. 
Results 
A total of $7,332,407 was paid to 2775 medical practitioners. Of these, 236 were medical oncologists, 
189 were haematologists and 1145 were other specialist physicians. This represents 31.7% of 
Australian medical oncologists and 30.9% of Australian haematologists, compared to 11.7% of all other 
specialist physicians and 1.1% of all other non-specialist physician medical practitioners. Medical 
oncologists received significantly higher payments (median $2,131.26) than other specialist physicians 
(median $1,376.00, 2-tailed p=0.004) and other medical practitioners (median $709.00, 2-tailed 
p<0.001), while haematologists received significantly higher payments (median $1,519.95) than other 
medical practitioners (2-tailed p<0.001), but similar payments to other specialist physicians (2-tailed 
p=0.08).  
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Conclusions 
Australian cancer physicians receive payments at a higher proportional frequency and in greater dollar 
amounts than other specialist physicians and other medical practitioners in general. 
This article is protected by copyright. All rights reserved.
This is the pre-peer reviewed version of the following article: Pokorny, A. M. J., Bero, L. A., Moynihan, R., & Mintzes, B. J. (2020). Industry 
 payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly-available disclosures. 
 Internal Medicine Journal, which has been published in final form at https://doi.org/10.1111/imj.15005. 
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Ver
Introduction 
Up to one in five people will die due to malignancy.(1) Drugs used to treat cancer are projected to 
represent almost 20% of the global medication market by 2024, more than four times the nearest 
competing therapy group.(2) These drugs have become more expensive with time, despite 
commentary arguing these increases are unsustainable.(3, 4) Given their control of sales revenues 
within this lucrative market, prescribers of these drugs are a likely target for influence by the 
pharmaceutical industry. 
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In Australia, the Commonwealth Therapeutic Goods Act (1989) dictates that all marketing of 
prescription medications must be directed at prescribers, and not consumers.(5) In the case of anti-
cancer treatments, these prescribers are medical oncologists and clinical haematologists, both 
recognised as subspecialists by the Royal Australasian College of Physicians (RACP) and endorsed as 
such by the Medical Board of Australia within the Australian Health Practitioner Regulation Agency 
(APHRA).(6) Collectively, they may be described as cancer physicians. 
Payments from pharmaceutical companies negatively influences prescribing practice, both for cancer 
physicians and other medical practitioners.(7-10) Prescribers who receive research funding, honoraria 
or sponsorship of conference travel show positive attitudes to the sponsor’s medications, prescribe 
the sponsor’s drug more and are more likely to request the sponsor’s drug on a hospital formulary.(11) 
Nonetheless, it is permissible in Australia for pharmaceutical companies to directly pay doctors for 
numerous services or events.  
Previous research into pharmaceutical expenditure in Australia has shown more sponsored events for 
medical oncologists and haematologists than other specialties.(12, 13) Approximately 13% of 
Australian medical oncologists report company sponsorship to attend Continuing Medical Education 
events, although this figure is limited by a low response rate and potential reporting bias.(14) 
However, no previous analysis has ever occurred of all direct payments from the pharmaceutical 
industry to Australian cancer physicians.  
In other jurisdictions, this has been explored in detail. In the United States, according to mandated 
industry disclosures, between  52.4% and 66.2% of oncologists receive direct funding.(15-17) In Japan, 
the rate is as high as 70.6%.(18) The equivalent frequency in Australia is unknown.  
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The majority of, but not all, pharmaceutical companies operating in Australia are members of 
Medicines Australia.(19) This organisation maintains a Code of Conduct by which its members are 
expected to abide. Since 2016, under the direction of the Australian Competition and Consumer 
Commission (ACCC), the Code has required members to disclose payments made to all health care 
practitioners, including medical practitioners. Since 2019, these are reported on a centralised, 
searchable website named Disclosure Australia.(20) Payments are reported on this website every six 
months, representing distinct “disclosure periods” that ended four months prior to the date of 
publication. 
Notably, the nature of disclosed expenditures by pharmaceutical companies changed after 2016.(21) 
While greater transparency now occurs for payments to individuals, specific payments are excluded, 
including provision of food and beverages either at sponsored events or within clinical settings. While 
this demonstrates both an improvement and weakening of industry disclosures, it underscores the 
need for analysis of the new dataset, as this reports a different form of industry spending in Australia. 
Aims 
We aimed to analyse the extent of payments from the pharmaceutical industry to Australian cancer 
physicians as reported during the first collated period of the Disclosures Australia website, and to 
compare these payments to those received by other medical practitioners. 
Methods 
Study design 
We performed a retrospective, cross-sectional analysis of payments made to Australian medical 
practitioners over a six-month period.  
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Source and participants 
In August 2019, Medicines Australia released its first collated record of pharmaceutical company 
payments to health practitioners via the Disclosure Australia website. These data related to payments 
made during a six-month period from November 2018 to April 2019 by all pharmaceutical company 
members of Medicines Australia. 
We obtained this full record directly from the publicly-available website as an Excel comma separated 
values (.csv) file. Within this file, each payment was listed separately to reflect specific situations 
resulting in remuneration. The information available for each payment consisted of the variables listed 
in Table 1. 
Table 1: Variables available directly from Disclosures Australia 
Company name 
Date of Event 
Healthcare professional (ie name) 
Healthcare professional type 
Practice address 
Type of service 
Type of event 
Payment made to (ie healthcare professional or third party) 
Registration fees (in AUD) 
Travel costs (in AUD) 
Fees for service (in AUD) 
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Additional demographic details available in the AHPRA 
Register of practitioners 
Specialty/ies recognised by AHPRA 
Medical school completion year 
Specialist fellowship certification year 
Australian medical council certification year (if overseas-
trained) 
The payments were then sorted by Healthcare professional type, with all payments to non-medical 
practitioners (eg, nurses, pharmacists) excluded from the analysis. Following this, the payments were 
sorted by Healthcare professional, so that multiple payments to individual practitioners could be 
identified.  
The names and addresses of each practitioner are the only identifying details available from Disclosure 
Australia. We cross-checked each name against records publicly available in the Register of 
practitioners on the Australian Health Practitioner Regulation Agency  (AHPRA) website in 2019.(22) 
We used these records to reliably identify as many of the medical practitioners listed as possible. 
When names could not be confirmed in the Register, an Internet search was performed using Google 
by name and practice location to provide more information. All non-medical practitioners or non-
practicing (eg academic) medical practitioners were then excluded. 
For each reliably identified medical practitioner, whenever possible we added the demographic 
information available in the Register but missing in the disclosure, as listed in Table 1. Most 
pertinently, we assigned specialties to each of the names. 
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We then classified practitioners into four separate groups based on specialties: medical oncologists, 
clinical haematologists, all other internal medicine specialists (ie other specialist physicians), and all 
remaining, non-specialist physician medical practitioners. The final group (ie all remaining medical 
practitioners) included any registered doctor who was not endorsed as an adult internal medicine 
subspecialist by the RACP and AHPRA. This included all general practitioners, non-medical specialists, 
paediatricians and trainee doctors, regardless of their potential specialty training program. 
For practitioners with both haematologist and medical oncologist registration, we classified their 
payments into their dominant specialty, determined through a combination of their publication 
histories and their usual fields of practice as advertised on official cancer centre websites. 
Analysis 
The payments made to each identified practitioner were combined to produce a total payment 
amount for each person during the disclosure period. We calculated the mean payment per group for 
comparison. We also calculated the number of individuals per group to compare to the total number 
of such practitioners in Australia based on the Register totals at June 2019,(23) to estimate 
proportions of practitioners in each group receiving payments. 
To further examine how payments to cancer physicians compared to other internal medicine 
specialists, we performed an exploratory post hoc analysis of payments by subspecialty type. In 
addition to medical oncologists and clinical haematologists, we assessed payments to cardiologists, 
endocrinologists, gastroenterologists, neurologists, respiratory physicians, rheumatologists, renal 
physicians and all remaining internal medicine specialists.  
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For medical oncologists and clinical haematologists specifically, we summarised the payment totals by 
specific companies in Australia as a whole, as well as the reasons listed for these payments.  
Statistics 
All statistical analyses took place using either SPSS v.26 (IBM, New York) or direct calculation. To 
initially assess normality of the data, histograms of payments were produced and a Shapiro-Wilk test 
was performed, confirming a positive (right) skewed distribution.  
Given the non-normal distribution of the payments, an independent-samples Kruskal-Wallis test was 
used to assess differences in total payments between the four pre-determined specialty groups.  
Mann-Whitney U tests were then specifically used to compare pairwise payments for pre-specified 
groups.  
The estimated comparative proportions of each practitioner group-type receiving payments were 
analysed using Fisher’s Chi-squared tests. For all tests, we considered a p-value of less than 0.05 
significant. 
Results 
Payments by Specialty Group 
There were 4832 reports of payments to medical practitioners provided as reimbursements during a 
six month period from November 2018 to April 2019. These payments related to events that took 
place from December 2015 to November 2019, as some payments were provided as reimbursements 
after the event occurred or in anticipation of an upcoming event. Values are expressed in 2019 
Australian dollars. 
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A total of $7,332,407 was paid to 2775 identified registered medical practitioners. Of these, 185 were 
registered as clinical haematologists, 233 were medical oncologists, seven were both clinical 
haematologists and medical oncologists, 1145 were other specialist physicians and 1205 were other, 
non-specialist physician medical practitioners. After classifying dual-registered cancer physicians into 
their dominant specialty the haematologist and medical oncologist group populations rose to 189 and 
236 respectively. 
Figure 1 above shows the payments per medical specialty by the percent of clinician per designated 
group receiving specific levels of payments. Given the skewed payment distribution, we assessed 
medians for each payment group, reported with full range and inter-quartile range (IQR), presented 
in Table 2. Medical oncologists received the highest median payments at $2,131.26 (IQR $844.65-
$5,653.06), followed by haematologists ($1,519.95, IQR $912.20-$3,621.57), other specialist 
physicians ($1,376.00, IQR $818.59-$3,412.82) and other non-specialist physician medical 
practitioners ($709.00, IQR $295.00-$1,345.00). We analysed these payment distributions using the 
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non-parametric Kruskal-Wallis test, rejecting the null hypothesis that the distribution of payments 
were the same across the specialties (p<0.001).  
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We then performed pairwise comparisons for the pre-specified specialty groups of interest using 
Mann-Whitney U tests. Specifically, we analysed four comparisons: medical oncologists versus other 
specialist physicians, medical oncologists versus other non-specialist physician medical practitioners, 
haematologists versus other specialist physicians and haematologists versus other non-specialist 
physician medical practitioners. 
Again using mean rank comparisons, we determined that medical oncologists received significantly 
higher payments than other specialist physicians (2-tailed p=0.004) and other medical practitioners 
(2-tailed p<0.001), while haematologists received significantly higher payments than other medical 
practitioners (2-tailed p<0.001). The amount received by haematologists did not differ significantly 
from other specialist physicians (2-tailed p=0.08). 
When compared against other internal medicine specialties, medical oncologists had the highest 
category total of payments, as well as the highest mean payment amount (also presented in Table 2). 















































This article is protected by copyright. All rights reserved.
This is the pre-peer reviewed version of the following article: Pokorny, A. M. J., Bero, L. A., Moynihan, R., & Mintzes, B. J. (2020). Industry 
 payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly-available disclosures. 
 Internal Medicine Journal, which has been published in final form at https://doi.org/10.1111/imj.15005. 
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Ver
$4,920.27). Haematologists had the third highest category total payments (after medical oncologists, 
endocrinologists and cardiologists), the fourth highest mean payment amount (after medical 
oncologists, rheumatologists and endocrinologists), and fifth highest median payment amount (after 
neurologists, medical oncologists, renal physicians, endocrinologists and respiratory physicians). 
These distribution differences were statistically significant using a Kruskal-Wallis test (p<0.001), and 
did not change our overall conclusions. 
Proportions of Specialists Receiving Payments 
Using contemporaneous Australian medical workforce summary data, we calculated the proportions 
of each defined speciality group receiving payments. These results are presented in Table 3, showing 
that approximately 32% of Australian medical oncologists and 31% of Australian haematologists 
received payments during the disclosure period. This compares to 12% of other internal medicine 
subspecialist physicians and only 1% of other, non-specialist physician medical practitioners. 
Table 3: Proportion of payment recipients by specialty group 
Specialty group Received 
payment (n) 
Total registered 
in Australia at 




Medical oncologists 240* 757 31.7 
Clinical haematologists 192* 621 30.9 
Other internal medicine specialist 
physicians (total) 
1145 9780 11.7 
Subgroups Cardiologists 219 1481 14.8 
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Endocrinologists 182 766 23.8 
Gastroenterologists 151 960 15.7 
Neurologists 88 677 13.0 
Respiratory 
physicians 
181 775 23.4 
Rheumatologists 103 404 25.5 
Renal physicians 54 610 8.9 
Other internal 
medicine specialists 
167 4107 4.1 
Other medical practitioners (non-
specialist physician) 
1205 107838 1.1 
*Includes dual-registered medical oncologists and clinical haematologists in both groups, consistent
with AHPRA workforce reporting. 
These proportions were analysed in the same crosswise pairings as the payment estimates. Fisher’s 
Chi-squared testing showed that the proportion of medical oncologists receiving payments was higher 
than other specialist physicians (p<0.001) and other medical practitioners (p<0.001).  The proportion 
of haematologists receiving payments was also higher than other specialist physicians (p<0.001) and 
other medical practitioners (p<0.001).  
In our exploratory post hoc analysis by subspecialties, the proportion of medical oncologists and 
haematologists who received payments was the highest and second highest respectively. Figures for 
each subspecialist group are additionally provided in Table 3. 
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Payments by Company 
Payments to medical oncologists and clinical haematologists by company are displayed in Figure 2, 
listed in descending total value. Payments to medical oncologists and clinical haematologists by 
category are displayed in Figure 3. 
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During the disclosure period, a total of 449 payments were made to medical oncologists, totalling 
$1,027,352.92. The highest total category of payment was for travel costs at $495,218.04, followed 
closely by service fees, including consulting and advisory panels, totalling $491,450.03. A total of 337 
payments were made to clinical haematologists, totalling $719,565.40. The highest total category of 
payment was for travel costs at $440,094.65, almost twice that paid for service fees at $243,967.78. 
For medical oncologists, the highest individual company payment came from Merck and its affiliates, 
the manufacturer of such drugs as pembrolizumab (~9,360 per cycle(24)) totalling $239,797.00. Merck 
also had the highest number of payments at 142. For haematologists, the highest company payment 
was from Celgene, which produces lenalidomide (~$6610 per cycle(24)) at $132,204.00. The highest 
number of payments was from Novartis, which produces nilotinib (~$5,220 per month(24)), at 86. For 
medical oncologists, the top five companies were responsible for 78% of all payments, while for clinical 
haematologists this figure was 70%. 
A full breakdown of payments to both medical oncologists and clinical haematologists is provided in 
the Supplementary Appendix. 
Discussion 
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This is the first direct analysis of pharmaceutical industry payments to medical oncologists and 
haematologists in Australia. Almost a third of cancer physicians received direct payments from 
November 2018 to April 2019, compared to 11 percent of other internal medicine subspecialist 
physicians and only one percent of GPs, trainees and other non-specialist physician medical 
practitioners.  The value of these payments was significantly higher to medical oncologists than both 
other medical practitioners and other specialist physicians, and was significantly higher to 
haematologists than other medical practitioners, but not other specialist physicians.  
For the pharmaceutical industry, anti-cancer medications are a hugely lucrative commodity, projected 
to provide up to US$237 billion in annual revenue globally by 2024, by far the largest market share of 
any disease group.(2) With the cost to consumers and governments rising, this study provides valuable 
information about conflicts of interest among cancer physicians, the prescribers of these medicines. 
By the RACP’s own standards, it is best practice to refuse payments from the pharmaceutical 
industry.(25) Despite these standards, payments continue to be received by cancer physicians on a 
large scale. 
Payments from pharmaceutical companies, regardless of the extent, influences prescribing practice, 
in a way that can potentially be detrimental for patient care.(7-10) Gifts of any value can create 
reciprocity.(26, 27) Receipt of just one sponsored meal in the US has been associated with increased 
prescribing of the sponsor’s brand-name drug.(15, 28) 
It is also known, specifically, that payments from the pharmaceutical industry can affect prescribing 
by cancer physicians. For example, oncologists in the US are more likely to prescribe some anti-cancer 
drugs over their competitors, such as sunitinib, dasatinib and nilotinib, if they have received payments 
from the drug’s manufacturer, despite no clear evidence of direct clinical superiority.(15) Authors of 
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oncology clinical practice guidelines and consensus statements are also more likely endorse specific 
drugs when they maintain financial conflicts of interest with their manufacturers.(29) This highlights 
the potential clinical ramifications of our findings. 
To some extent, interactions between cancer physicians and the pharmaceutical industry are at this 
time unavoidable. It is in the interest of patients to have access to major clinical trials, and these are 
frequently designed and sponsored by drug companies. Novel medications are often accessed by 
patients directly from drug companies ahead of federal funding, with cancer physicians acting as the 
prescribing intermediary.  
However, any interaction creates a conflict of interest. The fundamental role of a drug company is to 
maximise its profits, while the fundamental role of a cancer physician is to provide his or her patients 
with the best possible care. Financial relationships in particular have no demonstrable benefit for 
patients; to our knowledge, not a single previous study has shown industry payments to physicians to 
improve patient care. 
Furthermore, previous systematic reviews have explored the potential benefits of interactions with 
the pharmaceutical industry in general, and failed to identify improved outcomes for patients. Spurling 
et al found only a single study that could demonstrate any improvement in prescriber knowledge (in 
this case, the treatment of complex Lyme disease), but the same study showed the additional potential 
for harm (poorer knowledge of treatment for uncomplicated Lyme disease).(30) 
There are several limitations in this study, in large part due to limitations in the database itself. The 
first is that the limited scope of the disclosure period means it is difficult to accurately estimate annual 
payment rates, or the true number of clinicians receiving payments. It would be inaccurate to simply 
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double the six-monthly figures as this assumes such payments are regular, when the reality of this 
dataset is that payments were highly sporadic. 
These payments also represent a minority of the interactions that occur between doctors and the 
pharmaceutical industry. For example, they do not include attendance at events where drug 
companies sponsor food and beverages, nor do they take into account general interpersonal 
interactions between representatives and doctors. While such sponsored events were previously 
reported in Australia by individual companies, and discussed in the literature,(12) they no longer 
feature in contemporary disclosures. 
We additionally discovered and corrected some inaccuracies in categorisation of medical practitioners 
during our analysis. It is therefore conceivable that some misclassifications were missed when we 
initially excluded all non-medical health practitioners. This reflects an inaccuracy with the original data 
collection by Medicines Australia. 
The observational nature of this research also limits our understanding of why practitioners chose to 
receive these payments. Nor do we understand whether cancer physicians felt they were acting in the 
best interest of patients when providing a renumerated service, for example through the development 
of clinical trial protocols. This should be the focus of further research in this area, to better guide policy 
decisions around interactions with industry, particularly in the context of cancer physicians.  
In the US, payments to medical practitioners are mandatorily disclosed under the Open Payments 
(Sunshine) Act. The details for any given practitioner can be searched on the Open Payments 
website,(31) with that individual’s payments compared to other practitioners of the same specialty. 
Alternatively, the payments to all members of an entire speciality can be easily produced, and 
compared to other specialities. 
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This contrasts with a lack of clarity in the Medicines Australia model of disclosures. While the public is 
able to easily search for any given practitioner by name, the Disclosure Australia website does not 
allow this information to be understood in context. Indeed, this study has attempted to provide this 
context, but the current reporting mechanism is not adequate for what is ostensibly a method of 
providing accurate and open information to the public in perpetuity. 
It would be prudent for Australian disclosures to follow this US model. As it stands, the ACCC has 
overseen an inadequate form of reporting interactions with the pharmaceutical industry. 
Fundamentally, more detail needs to be collected and made available to the public. This is true both 
for direct payments to clinicians and other gifts provided by the industry, which are now lacking in 
disclosure reports. While the move to make collated disclosures easily searchable is commendable, 
this study shows that it does not go far enough. 
Conclusions 
Current payments to Australian cancer physicians from the pharmaceutical industry occur at a higher 
frequency than to other doctors in general and to other specialist physicians specifically. The extent 
of payments to medical oncologists is higher per practitioner than those made to other doctors and 
other specialist physicians, while haematologists receive higher payments than other doctors but not 
other specialist physicians. Manufacturers of expensive pharmaceuticals target Australian cancer 
physicians, frequently paying for specific advisory services and subsidising travel. 
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Figure 1: Distribution of payments by frequency for each of the four specified groups 
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Figure 2: Cumulative amount of payments by company name to (a) medical oncologists and (b) clinical 
haematologists. 
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Figure 3: Total payments by category to (a) medical oncologists and (b) clinical haematologists. 
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